Lowes heir Josh Penn and Ben Palmer's Point Piper home sells
Lowes heir Josh Penn and his husband Ben Palmer have sold their Wyuna Rd, Point Piper mansion for $23.5m.
The couple, with son Brooklyn, 6, and daughter Blake, 4, are now understood to be focusing on renovating the Penn family's palace at Cap 'd'ail in the south of France, where they're intending on spending some time next year.
And they're also now debating whether to move to their former Double Bay home, now rebuilt, or to another eastern suburbs mansion they've apparently purchased, that's 'quite substantial'.
Hush-hush sale hits 2025 record
Penn and Palmer are listed as co-owners on the land title for Capri, the Edwardian residence at 4 Wyuna Rd bought for $16m in 2021, alongside Penn's parents David and Linda Penn who have 70 per cent ownership.
But it's now sold via Monika Tu and Jad Khattar of Black Diamonz, with Tom Penfold of Cohen Handler known to have introduced the buyer.
There'd initially been hopes of $28m.
Penn and Palmer had been living in Capri during the three-year rebuild of their own home at 7 Carlotta Rd, Double Bay, bought for $6.7m in 2020, which is apparently 'incredible' and nearly ready to move into.
No clue yet as to the location of this other 'quite substantial' property, which is yet to settle.
The Wyuna Rd residence was previously owned by nursing-home scion Mark Moran and his interior decorator wife Evette.
The historic home on a 723sqm block had harbour views, an internal lift, multiple balconies, manicured grounds and a pool.
Penn and Palmer had initially intended to do major renovations, but ended up doing just landscaping the garden and adding lighting.
Their good taste in furniture helped give the home extra zing.
Josh Penn and mother Linda, the highly regarded philanthropist and CEO of Lowes Menswear that's worth $800m, recently raised a whopping $84.3m at the recent Gold Dinner for the Sydney Children's Hospital foundation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
22 minutes ago
- ABC News
Queenslanders push for further measures to enable home ownership
A Sunshine Coast woman who works four casual jobs but still can not save enough money for a home deposit says a new shared equity scheme for first home-buyers fails to address the root cause of housing stress. The Boost to Buy Home Equity program announced in this year's Queensland state budget was designed to help 1,000 eligible first home-buyers enter the property market. The government said it would contribute 30 per cent equity for new builds and 25 per cent for existing homes, for properties up to the value of $1 million. It was designed to allow Queenslanders to purchase a home with a two per cent deposit. Buderim woman Jade Weatherill said the scheme would not help low-income households spending more than 30 per cent of their income on rent. She said the equity home buying schemes were only accessible to couples or higher-income earners. "Those schemes are great when it's a couple and they're both working full time and they might be lucky enough to have parents help them out with the deposit," she said. "But a single woman on casual employment … I'm not even going to bother trying." Ms Weatherill said flexible mortgage structures that allowed people to qualify for a loan regardless of their income and pay it off at a lower rate over time would be a better option. Ms Weatherill, who works as a face painter, writer, artist, disability support worker, teacher's assistant and in retail, said she still was not earning enough to guarantee housing security. "Any full-time proper job that I try and apply for there's thousands of people [also applying] and you hardly even hear back," she said. "So, I take the casual jobs hoping for something better one day." She said real estate agents constantly turned her applications away because she was a casual worker. "I don't apply for rentals anymore because I don't earn enough," she said. "There is nothing affordable." She said she rented privately but having no record of renting and no regulation could cause issues. "Landlords want cash because they don't want to claim it on tax," Ms Weatherill said. "You've got no security. "Stop making housing an investment for the rich. "It's a human right." Queensland's property market has never been more expensive. The latest Real Estate Institute of Queensland (REIQ) data shows the median sale price for Queensland houses grew 0.61 per cent across the first three months of the year to $812,000. Real Estate Institute of Queensland (REIQ) data from March showed million-dollar medians were maintained in Noosa ($1.34m), Brisbane ($1.215m), Gold Coast ($1.15m) and Sunshine Coast ($1.077m). REIQ chief executive Antonia Mercorella said the latest figures reflected an active market in early 2025 and highlighted an exponential five-year transformation with some regions doubling in value. "In March 2020, as Australia was shutting its borders and grappling with economic uncertainly, Queensland's annual median house price was just $490,000," she said. "Today it's $790,000, representing a staggering 61.22 per cent increase. "Queensland units have similarly surged from $385,000 to $640,000 — a 66.23 per cent increase in the median sales price over the same five-year period. "As prices have climbed, units have become a popular go-to option for buyers seeking more affordable entry points." Singles earning up to $150,000 and households with two adults earning up to $225,000 will be eligible for the new shared equity scheme. The $30,000 first home buyers grant that was due to expire at the end of the month has been extended to June 2026. But Anglicare Southern Queensland chief executive Sue Cooke said research showed the scheme did not go far enough for the state's most vulnerable. "We understand that Queensland's Boost to Buy Home Equity scheme will enable some Queenslanders to purchase a home with a two per cent deposit," she said. "There is still some way to go in assisting low-income households to achieve home ownership." Ms Cooke said research from the Queensland Council of Social Service (QCOSS) on living affordability revealed people on low incomes were unable to make meaningful savings. "Making a deposit as small as two per cent is unachievable for many Queenslanders," she said. "There is an opportunity for the government to assist with these cost-of-living pressures by reconsidering measures such as the $1,000 energy relief to ensure all Queenslanders can receive a fair go at achieving home ownership." Ms Cooke said mortgage guarantees and targeted shared equity arrangements, replacing stamp duty with universal land tax, and/or increasing the stamp duty threshold and land lease arrangements would make a more meaningful difference. "Whilst we welcome funding announcement for social housing to achieve the LNP's ambitious commitment to deliver over 2,000 homes in its first year; we are keen to understand specific detail of the Securing our Housing Foundations Plan, including how 52,000 people currently on the social housing waitlist will be supported," she said.
The Australian
40 minutes ago
- The Australian
StockTake: Star Minerals
Stockhead's Tylah Tully unpacks the latest from Star Minerals (ASX:SMS), as it endeavours to grow the gold resource at its Tumblegum South gold project. Star is testing for more high-grade lodes that could add to the resource and bolster the potential mine life. Watch the video to learn more. This video was developed in collaboration with Star Minerals, a Stockhead advertiser at the time of publishing. This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Daily Telegraph
an hour ago
- Daily Telegraph
LTR Pharma completes ED study milestone
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. LTR Pharma & co-development partner Aptar Pharma complete extractables study on SPONTAN All identified compounds below ICH safety thresholds for nasal spray-mist erectile dysfunction treatment Leachables study initiated to support FDA regulatory submission under real-world storage conditions Special Report: LTR Pharma has completed a key extractables study for its SPONTAN intranasal spray for erectile dysfunction and kicked off a leachables study as part of a regulatory development program. LTR Pharma (ASX:LTP) said the extractables study, conducted under the supervision of co-development partner Aptar Pharma, evaluated the bottle and pump components of SPONTAN's container closure system. The study confirmed that all detected compounds were below ICH safety thresholds – the internationally recognised standards adopted by the US Food and Drug Administration (FDA) and regulatory authorities worldwide for pharmaceutical impurities. LTR Pharma said the identified compounds would be monitored in the ongoing leachables study. FDA requires extractables and leachables (E&L) studies for all pharmaceutical products to ensure packaging materials do not compromise product safety or efficacy. For nasal spray products, these studies must meet specific regulatory thresholds due to direct tissue exposure. Leachables study now underway The leachables study has started under Aptar Pharma's management, evaluating the potential migration of the compounds from packaging into SPONTAN under real-world storage conditions. LTR Pharma said SPONTAN used industry-standard bottle and pump components as used in multiple FDA-approved nasal spray products. The study will run for at least 24 months to support shelf-life requirements. Consistent with FDA practice for nasal sprays, the company can submit its application once sufficient robust data is available, with study completion continuing post-approval as standard. E&L studies form part of LTR Pharma's comprehensive regulatory strategy following its FDA pre-IND meeting, where the FDA confirmed the proposed development pathway. The company said E&L data were required for the chemistry, manufacturing and controls (CMC) section of its planned new drug application (NDA). With extractables results meeting regulatory requirements, the company progresses to the leachables phase for comprehensive regulatory submission data. Watch: LTR's new appointment Progress on SPONTAN and new US-targeted ROXUS LTR Pharma continues to progress SPONTAN through established regulatory pathways while building commercial foundations through its Australian early access programs. It is also progressing its new ED nasal spray called ROXUS, which offers a fast-track pathway to serve patients through the US personalised healthcare sector. As with SPONTAN, ROXUS is based on the common active ingredient vardenafil. It will be delivered via the 503(a)-compounding pharmacy pathway, which exempts drugs from the usual approval, labelling and manufacturing requirements. "The completion of our extractables study and commencement of the leachables phase keep our regulatory program on schedule,' LTR Pharma executive chairman Lee Rodne said. 'Working with Aptar Pharma provides us with their established expertise in nasal spray device development and FDA submissions. 'These studies are necessary steps in our development pathway, and we look forward to progressing through each regulatory milestone." This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as LTR Pharma completes study milestone for SPONTAN ED treatment
